Europe Cell and Gene Therapy Manufacturing QC Market Size, Share & Trends Analysis Report By Therapy Type (Cell Therapy, Gene Therapy), By Scale (Pre-commercial/R&D, Commercial), By Mode (Contract, In-house), By Workflow (Cell Processing, Cell Banking, Fill & Finish, Raw Material Testing, Vector Production, Others), By Process (Upstream, Downstream), By End User (Pharmaceutical, Biopharmaceutical/Biotechnology Companies, CMOs), By Technology (FACS, ELISA, Chromatography, NGS, PCR, Others), By Country (U.K., Germany, France, Italy, Russia, Nordic, Benelux, Rest of Europe), Forecasts, 2026–2034.

Last Updated: July 08, 2026 | Author: Debashree B | Format:

Market Segmentation

  1. Europe Cell and Gene Therapy Manufacturing QC Market, By Therapy Type 2022 (USD MILLION/ Units)
    1. Cell Therapy
      1. CAR-T
        1. Autologous CAR-T
        2. Allogeneic CAR-T
      2. CAR-NK
      3. B-Cell
      4. Others
    2. Gene Therapy
      1. Viral
        1. AAV
        2. Lentiviral vectors
        3. Other
      2. Non-Viral
  2. Europe Cell and Gene Therapy Manufacturing QC Market, By Scale 2022 (USD MILLION/ Units)
    1. Pre-commercial/ R&D Manufacturing
    2. Commercial Scale Manufacturing
  3. Europe Cell and Gene Therapy Manufacturing QC Market, By Mode 2022 (USD MILLION/ Units)
    1. Contract Manufacturing
    2. In-house Manufacturing
  4. Europe Cell and Gene Therapy Manufacturing QC Market, By Workflow 2022 (USD MILLION/ Units)
    1. Cell Processing
    2. Cell Banking
    3. Fill & Finish Operations
    4. Raw Material Testing
    5. Vector Production
    6. Other Workflows
  5. Europe Cell and Gene Therapy Manufacturing QC Market, By Process 2022 (USD MILLION/ Units)
    1. Upstream Processes
    2. Downstream Processes
  6. Europe Cell and Gene Therapy Manufacturing QC Market, By End-User 2022 (USD MILLION/ Units)
    1. Pharmaceutical Companies
      1. Small Size
      2. Medium Size
      3. Large Size
    2. Biopharmaceutical / Biotechnological Companies
      1. Small Size
      2. Medium Size
      3. Large Size
    3. Contract Manufacturing Organizations
      1. Small Size
      2. Medium Size
      3. Large Size
  7. Europe Cell and Gene Therapy Manufacturing QC Market, By Technology Type 2022 (USD MILLION/ Units)
    1. Fluorescence-Activated Cell Sorting (FACS)
    2. Enzyme-Linked Immunosorbent Assay (ELISA)
    3. Chromatography
    4. Next-Generation Sequencing (NGS)
    5. Polymerase Chain Reaction (PCR)
    6. Others
  8. Regional Europe Cell and Gene Therapy Manufacturing QC Market
    1. Europe
      1. Europe Europe Cell and Gene Therapy Manufacturing QC Market By Therapy Type 2022 (USD MILLION/ Units)
        1. Cell Therapy
          1. CAR-T
            1. Autologous CAR-T
            2. Allogeneic CAR-T
          2. CAR-NK
          3. B-Cell
          4. Others
        2. Gene Therapy
          1. Viral
            1. AAV
            2. Lentiviral vectors
            3. Other
          2. Non-Viral
      2. Europe Europe Cell and Gene Therapy Manufacturing QC Market By Scale 2022 (USD MILLION/ Units)
        1. Pre-commercial/ R&D Manufacturing
        2. Commercial Scale Manufacturing
      3. Europe Europe Cell and Gene Therapy Manufacturing QC Market By Mode 2022 (USD MILLION/ Units)
        1. Contract Manufacturing
        2. In-house Manufacturing
      4. Europe Europe Cell and Gene Therapy Manufacturing QC Market By Workflow 2022 (USD MILLION/ Units)
        1. Cell Processing
        2. Cell Banking
        3. Fill & Finish Operations
        4. Raw Material Testing
        5. Vector Production
        6. Other Workflows
      5. Europe Europe Cell and Gene Therapy Manufacturing QC Market By Process 2022 (USD MILLION/ Units)
        1. Upstream Processes
        2. Downstream Processes
      6. Europe Europe Cell and Gene Therapy Manufacturing QC Market By End-User 2022 (USD MILLION/ Units)
        1. Pharmaceutical Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        2. Biopharmaceutical / Biotechnological Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        3. Contract Manufacturing Organizations
          1. Small Size
          2. Medium Size
          3. Large Size
      7. Europe Europe Cell and Gene Therapy Manufacturing QC Market By Technology Type 2022 (USD MILLION/ Units)
        1. Fluorescence-Activated Cell Sorting (FACS)
        2. Enzyme-Linked Immunosorbent Assay (ELISA)
        3. Chromatography
        4. Next-Generation Sequencing (NGS)
        5. Polymerase Chain Reaction (PCR)
        6. Others
      8. U.K.
        1. Cell Therapy
          1. CAR-T
            1. Autologous CAR-T
            2. Allogeneic CAR-T
          2. CAR-NK
          3. B-Cell
          4. Others
        2. Gene Therapy
          1. Viral
            1. AAV
            2. Lentiviral vectors
            3. Other
          2. Non-Viral
        3. Pre-commercial/ R&D Manufacturing
        4. Commercial Scale Manufacturing
        5. Contract Manufacturing
        6. In-house Manufacturing
        7. Cell Processing
        8. Cell Banking
        9. Fill & Finish Operations
        10. Raw Material Testing
        11. Vector Production
        12. Other Workflows
        13. Upstream Processes
        14. Downstream Processes
        15. Pharmaceutical Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        16. Biopharmaceutical / Biotechnological Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        17. Contract Manufacturing Organizations
          1. Small Size
          2. Medium Size
          3. Large Size
        18. Fluorescence-Activated Cell Sorting (FACS)
        19. Enzyme-Linked Immunosorbent Assay (ELISA)
        20. Chromatography
        21. Next-Generation Sequencing (NGS)
        22. Polymerase Chain Reaction (PCR)
        23. Others
      9. Germany
        1. Cell Therapy
          1. CAR-T
            1. Autologous CAR-T
            2. Allogeneic CAR-T
          2. CAR-NK
          3. B-Cell
          4. Others
        2. Gene Therapy
          1. Viral
            1. AAV
            2. Lentiviral vectors
            3. Other
          2. Non-Viral
        3. Pre-commercial/ R&D Manufacturing
        4. Commercial Scale Manufacturing
        5. Contract Manufacturing
        6. In-house Manufacturing
        7. Cell Processing
        8. Cell Banking
        9. Fill & Finish Operations
        10. Raw Material Testing
        11. Vector Production
        12. Other Workflows
        13. Upstream Processes
        14. Downstream Processes
        15. Pharmaceutical Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        16. Biopharmaceutical / Biotechnological Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        17. Contract Manufacturing Organizations
          1. Small Size
          2. Medium Size
          3. Large Size
        18. Fluorescence-Activated Cell Sorting (FACS)
        19. Enzyme-Linked Immunosorbent Assay (ELISA)
        20. Chromatography
        21. Next-Generation Sequencing (NGS)
        22. Polymerase Chain Reaction (PCR)
        23. Others
      10. France
        1. Cell Therapy
          1. CAR-T
            1. Autologous CAR-T
            2. Allogeneic CAR-T
          2. CAR-NK
          3. B-Cell
          4. Others
        2. Gene Therapy
          1. Viral
            1. AAV
            2. Lentiviral vectors
            3. Other
          2. Non-Viral
        3. Pre-commercial/ R&D Manufacturing
        4. Commercial Scale Manufacturing
        5. Contract Manufacturing
        6. In-house Manufacturing
        7. Cell Processing
        8. Cell Banking
        9. Fill & Finish Operations
        10. Raw Material Testing
        11. Vector Production
        12. Other Workflows
        13. Upstream Processes
        14. Downstream Processes
        15. Pharmaceutical Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        16. Biopharmaceutical / Biotechnological Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        17. Contract Manufacturing Organizations
          1. Small Size
          2. Medium Size
          3. Large Size
        18. Fluorescence-Activated Cell Sorting (FACS)
        19. Enzyme-Linked Immunosorbent Assay (ELISA)
        20. Chromatography
        21. Next-Generation Sequencing (NGS)
        22. Polymerase Chain Reaction (PCR)
        23. Others
      11. Italy
        1. Cell Therapy
          1. CAR-T
            1. Autologous CAR-T
            2. Allogeneic CAR-T
          2. CAR-NK
          3. B-Cell
          4. Others
        2. Gene Therapy
          1. Viral
            1. AAV
            2. Lentiviral vectors
            3. Other
          2. Non-Viral
        3. Pre-commercial/ R&D Manufacturing
        4. Commercial Scale Manufacturing
        5. Contract Manufacturing
        6. In-house Manufacturing
        7. Cell Processing
        8. Cell Banking
        9. Fill & Finish Operations
        10. Raw Material Testing
        11. Vector Production
        12. Other Workflows
        13. Upstream Processes
        14. Downstream Processes
        15. Pharmaceutical Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        16. Biopharmaceutical / Biotechnological Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        17. Contract Manufacturing Organizations
          1. Small Size
          2. Medium Size
          3. Large Size
        18. Fluorescence-Activated Cell Sorting (FACS)
        19. Enzyme-Linked Immunosorbent Assay (ELISA)
        20. Chromatography
        21. Next-Generation Sequencing (NGS)
        22. Polymerase Chain Reaction (PCR)
        23. Others
      12. Russia
        1. Cell Therapy
          1. CAR-T
            1. Autologous CAR-T
            2. Allogeneic CAR-T
          2. CAR-NK
          3. B-Cell
          4. Others
        2. Gene Therapy
          1. Viral
            1. AAV
            2. Lentiviral vectors
            3. Other
          2. Non-Viral
        3. Pre-commercial/ R&D Manufacturing
        4. Commercial Scale Manufacturing
        5. Contract Manufacturing
        6. In-house Manufacturing
        7. Cell Processing
        8. Cell Banking
        9. Fill & Finish Operations
        10. Raw Material Testing
        11. Vector Production
        12. Other Workflows
        13. Upstream Processes
        14. Downstream Processes
        15. Pharmaceutical Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        16. Biopharmaceutical / Biotechnological Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        17. Contract Manufacturing Organizations
          1. Small Size
          2. Medium Size
          3. Large Size
        18. Fluorescence-Activated Cell Sorting (FACS)
        19. Enzyme-Linked Immunosorbent Assay (ELISA)
        20. Chromatography
        21. Next-Generation Sequencing (NGS)
        22. Polymerase Chain Reaction (PCR)
        23. Others
      13. Nordic
        1. Cell Therapy
          1. CAR-T
            1. Autologous CAR-T
            2. Allogeneic CAR-T
          2. CAR-NK
          3. B-Cell
          4. Others
        2. Gene Therapy
          1. Viral
            1. AAV
            2. Lentiviral vectors
            3. Other
          2. Non-Viral
        3. Pre-commercial/ R&D Manufacturing
        4. Commercial Scale Manufacturing
        5. Contract Manufacturing
        6. In-house Manufacturing
        7. Cell Processing
        8. Cell Banking
        9. Fill & Finish Operations
        10. Raw Material Testing
        11. Vector Production
        12. Other Workflows
        13. Upstream Processes
        14. Downstream Processes
        15. Pharmaceutical Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        16. Biopharmaceutical / Biotechnological Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        17. Contract Manufacturing Organizations
          1. Small Size
          2. Medium Size
          3. Large Size
        18. Fluorescence-Activated Cell Sorting (FACS)
        19. Enzyme-Linked Immunosorbent Assay (ELISA)
        20. Chromatography
        21. Next-Generation Sequencing (NGS)
        22. Polymerase Chain Reaction (PCR)
        23. Others
      14. Benelux
        1. Cell Therapy
          1. CAR-T
            1. Autologous CAR-T
            2. Allogeneic CAR-T
          2. CAR-NK
          3. B-Cell
          4. Others
        2. Gene Therapy
          1. Viral
            1. AAV
            2. Lentiviral vectors
            3. Other
          2. Non-Viral
        3. Pre-commercial/ R&D Manufacturing
        4. Commercial Scale Manufacturing
        5. Contract Manufacturing
        6. In-house Manufacturing
        7. Cell Processing
        8. Cell Banking
        9. Fill & Finish Operations
        10. Raw Material Testing
        11. Vector Production
        12. Other Workflows
        13. Upstream Processes
        14. Downstream Processes
        15. Pharmaceutical Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        16. Biopharmaceutical / Biotechnological Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        17. Contract Manufacturing Organizations
          1. Small Size
          2. Medium Size
          3. Large Size
        18. Fluorescence-Activated Cell Sorting (FACS)
        19. Enzyme-Linked Immunosorbent Assay (ELISA)
        20. Chromatography
        21. Next-Generation Sequencing (NGS)
        22. Polymerase Chain Reaction (PCR)
        23. Others
      15. Rest of Europe
        1. Cell Therapy
          1. CAR-T
            1. Autologous CAR-T
            2. Allogeneic CAR-T
          2. CAR-NK
          3. B-Cell
          4. Others
        2. Gene Therapy
          1. Viral
            1. AAV
            2. Lentiviral vectors
            3. Other
          2. Non-Viral
        3. Pre-commercial/ R&D Manufacturing
        4. Commercial Scale Manufacturing
        5. Contract Manufacturing
        6. In-house Manufacturing
        7. Cell Processing
        8. Cell Banking
        9. Fill & Finish Operations
        10. Raw Material Testing
        11. Vector Production
        12. Other Workflows
        13. Upstream Processes
        14. Downstream Processes
        15. Pharmaceutical Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        16. Biopharmaceutical / Biotechnological Companies
          1. Small Size
          2. Medium Size
          3. Large Size
        17. Contract Manufacturing Organizations
          1. Small Size
          2. Medium Size
          3. Large Size
        18. Fluorescence-Activated Cell Sorting (FACS)
        19. Enzyme-Linked Immunosorbent Assay (ELISA)
        20. Chromatography
        21. Next-Generation Sequencing (NGS)
        22. Polymerase Chain Reaction (PCR)
        23. Others

We are featured on: